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ABSTRACT
Core members of the MBD protein family (MeCP2,
MBD1, MBD2 and MBD4) share a methyl-CpG-
binding domain that has a specific affinity for
methylated CpG sites in double-stranded DNA.
By multimerizing the MDB domain of Mbd1, we
engineered a poly-MBD protein that displays methyl-
CpG-specific binding in vitro with a dissociation
constant that is .50-fold higher than that of a
monomeric MBD. Poly-MBD proteins also localize to
methylated foci in cells and can deliver a functional
domain to reporter constructs in vivo. We propose
that poly-MBD proteins are sensitive reagents for
the detection of DNA methylation levels in isolated
native DNA and for cytological detection of chro-
mosomal CpG methylation.
INTRODUCTION
Proteins that have been demonstrated to bind specifically to
methylated DNA belong to two characterized families. The
methyl-CpG-binding domain (MBD) family comprises five
polypeptides in mammals, four of which MBD1, MBD2,
MBD4 and MeCP2 have been shown to preferentially bind
a symmetrically methylated CpG motif (1–3). These proteins
share the MBD which confers specific DNA binding (4). The
unrelated Kaiso protein family binds to DNA sequences con-
taining methyl-CpGs via a distinctive zinc finger motif (5,6).
In keeping with evidence that DNA methylation is a signal
for transcriptional repression, MeCP2, MBD1, MBD2 and
Kaiso all repress transcription in vitro and associate with
co-repressors (1,5,7–10).
The aim of the present study was to harness the affinity of
the MBD to create a superior reagent for the detection of
methyl-CpG in vitro and in vivo. Assessment of global levels
of DNA methylation currently relies on mass spectrometry
(11), ‘nearest neighbour’ methods (12), enzymatic methyl-
group acceptance assays (13) or HPLC analysis (14). These
quantitative measures are complemented by the use of anti-
bodies against 5-methylcytosine (m5C), which in addition to
quantification permit visualization of m5C distribution within
DNA or chromosomes (15,16). A disadvantage of anti-m5C
antibodies is that the epitope is best exposed when DNA is
single-stranded and DNA must therefore normally be dena-
tured before detection. The MBD, on the other hand, is
specific for native double-stranded DNA. Another potential
benefit of the MBD reagent would be its specificity for
m5C in the context of a symmetrically methylated CpG
sequence (4).
To test the MBD reagent, we designed a series of artificial
methyl-CpG-binding proteins based on multimerization of
the MBD of Mbd1. The resulting polypeptides bound
strongly to methylated DNA with high specificity and could
compete with other methyl-CpG-binding proteins for DNA
binding in vitro. When expressed in vivo, the poly-MBD
protein localized to the methyl-CpG-rich heterochromatic
foci of mouse cells and could recruit a functional domain spe-
cifically to methylated DNA sequences. Poly-MBD proteins
proved to be sensitive and specific reagents for the detection
of methyl-CpGs in immobilized DNA and cytological
preparations.
MATERIALS AND METHODS
Plasmids
To generate constructs encoding the poly-MBD with varying
numbers of MBDs, two PCR fragments (PCR-A and PCR-B)
were amplified from each of the templates pFlag-mMBD1
or pFlag-mMBD1-R22A (17) to produce the wild-type and
R22A control constructs, respectively. PCR-A was amplified
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using primers 50-GCGAATTCGATGCCAAAAAAGAA-
GAGAAAGGTAGATATCATGGCTGAGTCCTGGCAGG-
ACTGCC-30 and 50-GCTCTAGACACGTGTTAAGCGT-
AGTCTGGGACGTCGTATGGGTACTTGGGAATGGGA-
TGGCATAAGG-30. It encodes a N-terminal nuclear localiza-
tion signal (NLS), cDNA from mouse Mbd1 corresponding to
amino acids 1–75 and a C-terminal HA-tag. In addition, it has
a 50 EcoRI site, a EcoRV site just downstream of the NLS, a
PmlI site just downstream of the HA-tag and a 30 XbaI site.
PCR-B was amplified using primers 50-AAGGTAGATA-
TCATGGCTGAGTCCTGGCAGGACTGCC-30 and 50-CT-
AGACACGTGAGAACCACCACCACCAGAACCACCAC-
CACCCTTGGGAATGGGATGGCATAAGG-30. It encodes
a mouse Mbd1 fragment corresponding to amino acids
1–75 followed by a flexible linker [(Gly4-Ser)2] with a
50 EcoRV and a 30 PmlI site. The pTRE-1xMBD construct
was made by inserting EcoRI/XbaI digested PCR-A
into EcoRI/XbaI opened pTRE (Clontech). Poly-MBD
constructs were made by inserting PmlI/EcoRV digested
PCR-B into an EcoRV cut MBD construct. A PCR fragment
encoding the activation domain of VP16 was inserted
between the NLS and the first MBD using the EcoRV site,
creating pTRE-NxMBD-VP16. For expression, the inserts
were excised using EcoRI/XbaI and transferred into
pET30b+ (pET-NxMBD, bacterial expression), pcDNA3 (p-
NxMBD, mammalian expression) or pLZRS-MS (pLZRS-
NxMBD, retroviral delivery). The retroviral shuttle vector
has been described previously (18). Reporter plasmids
(pRL-TK and pGL2-control) are from Promega.
Cell lines and retroviral infection
DNA methylation deficient Dnmt1 n/n (19), p53/ mouse
embryonic fibroblasts [described in (17)] were maintained
in DMEM (Gibco) supplemented with 15% bovine calf
serum, non-essential amino acids, sodium pyruvate and
antibiotics (Gibco). The presence of a homozygous p53 muta-
tion allows survival of Dnmt1-deficient cells (20). Phoenix
packaging cells were grown in DMEM and wild-type mouse
fibroblasts in MEM alpha, all supplemented with 10% bovine
calf serum and antibiotics (Gibco). Production of virus parti-
cles and infection of adherent cells was performed as
described (http://www.stanford.edu/group/nolan/index.html).
Cell lines expressing N-MBD proteins were made by retrovi-
ral infection.
Transfection and reporter gene activity
Reporter constructs were either M.SssI or mock methylated
and co-transfected with p-NxMBD expression constructs
plus a non-modified internal transfection control. The amount
of expression construct was kept constant by adding empty
vector (pcDNA3). Cells were transfected using Lipo-
fectamine (Invitrogen) or JetPEI (QBiogene) according to
the manufacturer’s instructions. Reporter gene activity and
activity of the internal transfection control was measured
40–48 h after transfection using the Dual Luciferase system
(Promega) according to the manufacturer’s instructions.
Each transfection was performed in triplicate and repeated
at least twice. Reporter activity is expressed relative to
the internal control activity to correct for differences in
transfection efficiency.
Recombinant proteins
Recombinant His6-tagged NxMBD proteins were purified
from 750 ml induced BL21(DE3) cultures on Ni-NTA agar-
ose (Qiagen) using denaturation and on column renaturation
cycles in accordance with the manufacturer’s instructions.
Recombinant GST-MeCP2 was made as described previously
(4). Nuclear extracts were made from mouse fibroblasts as
described previously (21).
Bandshifts
Binding reactions including purified His-tagged NxMBD
protein, recombinant MeCP2 or nuclear extract in 20 mM
HEPES, pH 7.9, 3 mM MgCl2, 10% glycerol, 1 mM dithio-
threitol, 100 mM KCl and 0.05 mg/ml sonicated Escherichia
coli DNA (Sigma) were pre-incubated 10 min at room
temperature before the addition of 25 fmol end-labelled
double-stranded probe. For supershift reactions anti-His6
(Santa Cruz, G-18) or anti-MBD3 (Santa Cruz, C-18) was
added. After a further 25 min incubation at room temperature,
the reactions were loaded on to either 6% polyacrylamide/
0.5· TBE gels and run for 2 h at 240 V (4C) or 1.3%
agarose/0.5· TBE gels and run at 6 V/cm (4C). Polyacryl-
amide gels were dried on to 3 mm Whatman paper and agar-
ose gels on to DE81 (Whatman). Radioactivity was detected
using a phosphor-screen and a Storm 840. All oligonucleotide
probes (3ME, 2ME, 1ME, 0ME) used for bandshift are based
on the sequence 50-ATCAGACGTTCGCCGGCGGATTGG-
CTTGGCTGCGAAGAAGATA-30 and the complementary
strand. In 3ME all the underlined CpGs are symmetrically
methylated, in 2ME C17 and C33 are methylated and in
1ME C17 is methylated whereas all CpG sites in 0ME are
left unmethylated. The oligonucleotides were annealed in
10 mM Tris–HCl, pH 8, 1 mM EDTA and 50 mM NaCl.
The CG11 probe is described previously (22), the methylated
version is methylated at all CpG dinucleotides by M.Sss I.
Immunostaining
Cells were fixed in 4% paraformaldehyde in PBS for 20 min
at room temperature followed by permeabilization in 0.2%
Triton X-100 in PBS. Slides were blocked in 3% BSA/PBS
before incubation with primary antibody (anti-HA, Santa
Cruz F-7, 1:1000) for 60 min. After washing and incubation
with Alexa-594 coupled anti-mouse antibody (1:1000,
Molecular Probes), slides were washed and mounted in
Vectashield with DAPI (Vector). Images were obtained
using a Zeiss microscope fitted with a CCD camera and pro-
cessed using Adobe PhotoShop or a Delta Vision deconvolu-
tion microscope and SoftWorx software.
Staining purified DNA using NxMBD proteins
Native double-stranded mock- or M.SssI-methylated lambda
phage DNA was slot-blotted on to Nytran Supercharge
membrane (Schleicher & Schuell) and immobilized by UV
crosslinking. Alternatively, DNA was denatured by incuba-
tion at 95C for 10 min, transferred and immobilized on
Optitran membrane (Schleicher & Schuell). The filters were
blocked 2 h at room temperature or ON at 4C and incubated
with purified recombinant NxMBD proteins (10 mg/ml) for
2 h at room temperature. After washing, the bound protein
was detected by incubation with first anti-HA antibody
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(1:500, F-7, Santa Cruz), then horseradish peroxidase coupled
anti-mouse antibody (1: 5000, Amersham). For detection
using anti-m5C antibody, the NxMBD and anti-HA incuba-
tions were substituted by a 1 h incubation with anti-m5C anti-
body (1:500, Eurogentec). All incubations were in TBS-T
supplemented with 5% skimmed milk powder. The blots
were developed by enhanced chemiluminescence and
exposed to film.
Staining cells using NxMBD proteins
Attached mouse fibroblasts were permeabilized for 2 min on
ice in 0.2% Triton X-100 in PBS and fixed 15 min at room
temperature in 4% paraformaldehyde in PBS. The cells
were incubated with purified recombinant NxMBD protein
diluted in PBS/10% goat serum for 2 h, washed and fixed
again for 15 min with 4% paraformaldehyde in PBS. The
NxMBD protein was detected by incubation with first
anti-HA antibody (1:500, F-7, Santa Cruz), then Alexa-594
coupled anti-mouse antibody (1:1000, Molecular probes).
The cells were counterstained with DAPI and mounted in
Vectashield (Vector). The cells were examined using a
DeltaVision deconvolution microscope with SoftWorx soft-
ware. Metaphase spreads were obtained from mouse fibrob-
lasts arrested 2 h with 0.1 mg/ml colcimid. Trypsinized
cells were swollen 10 min in 75 mM KCl, and adjusted
to 0.1% Tween-20 before spinning 20 000 cells on to slides
[cytospin 3 (Shandon), 800 r.p.m., 4 min]. After air drying,
the slides were equilibrated with KCM buffer (10 mM
Tris–HCl, pH 8, 120 mM KCl, 20 mM NaCl, 0.5 mM
EDTA and 0.1% Triton X-100) before incubating with puri-
fied recombinant NxMBD protein diluted in KCM plus 10%
goat serum for 1–2 h. After washing, the cells were fixed in
3% formaldehyde in KCM. The NxMBD protein was
detected by incubation with first anti-HA antibody (1:500,
F-7, Santa Cruz), then Alexa-594 coupled anti-mouse anti-
body (1:1000, Molecular probes). The slides were fixed
in 3% formaldehyde in KCM followed by counterstaining
and mounting in Vectashield with DAPI (Vector). The
chromosomes were examined as above.
RESULTS AND DISCUSSION
Multimerization of MBDs increases their affinity for
methylated DNA
To create a high-affinity methyl-CpG-binding protein, we
chose the MBD of Mbd1 as it is well characterized biochemi-
cally and structurally and is known to recognize a single
methylated CpG (1,23). Moreover, the transcriptional repres-
sion domain and the recently identified DNA-binding CXXC
domain of Mbd1 could be easily excluded from the construct
as both map to regions distant from the MBD (17,24). To
increase the binding affinity, multiple copies of the MBD
were linked together, connected by flexible linker peptides,
to generate ‘NxMBD’ polypeptides, where N is the number
of MBDs. Increased binding of a poly-MBD protein to a
methylated DNA molecule is expected for two reasons.
(i) Each protein molecule has a higher concentration of
DNA-binding sites than does a single MBD and, therefore,
the probability of a stable interaction resulting from a
DNA–protein collision is increased. Also, when a complex
dissociates, the local concentration of MBDs is higher than
for one MBD, favouring rebinding. (ii) The poly-MBD can
interact with several sites on a DNA molecule with multiple
mCpGs, thereby increasing the stability of the complex.
Multimerization of a DNA-binding domain has previously
been shown to create a high-affinity multi-AT-hook protein
(25). In addition, the poly-MBD protein included an
N-terminal NLS and was equipped with a C-terminal HA-
tag for detection purposes (Figure 1A). Negative control
proteins in which each MBD carried the R22A point mutation
that disrupts DNA binding (23) were created in parallel
(NxMBD–R22A).
Recombinant His6-tagged 1xMBD and 4xMBD proteins
were expressed in bacteria, purified to homogeneity
(Figure 1B) and tested for in vitro DNA-binding. Bandshift
analysis demonstrated that the wild-type proteins specifi-
cally form complexes with a methylated probe containing
27 methylated CpGs, but no binding of the mutant control
proteins was observed (Figure 1C). The ladder of complexes
reflects the varying number of proteins associated with each
DNA probe molecule (4). The hypothesis that the multimer-
ization of this domain would enhance its binding affinity was
tested by titrating identical weights of monomeric (1xMBD)
or tetrameric (4xMBD) proteins (Figure 2A and B) into
Figure 1. A multimerized-MBD protein binds to methylated DNA. (A)
Diagram of engineered wild-type (NxMBD) and mutant (NxMBD–R22A)
proteins with 1 or 4 MBDs. Asterisks mark the position of the inactivating
point mutation (R22A). The NLS is in grey, the MBD in white and the HA-
tag in black. An N-terminal His6-tag, which is present in bacterially expressed
proteins, is hatched. The insertion point of the VP16-activation domain
(VP16) is indicated. (B) A coomassie-stained polyacrylamide gel showing
purified 4xMBD (4·) and 1xMBD (1·). (C) Increasing amounts (2.5, 5, 10,
25, 50 ng) of wild-type (4xMBD) or negative control (4xMBD–R22A)
tetrameric MBD proteins were incubated with M.SssI-methylated (M) or non-
methylated (U) CG11 probe that contains 27 CpG sites (22). The complexes
were resolved on 1.3% agarose gels. The ladder of bands is due to complexes
that contain multiple protein molecules on a single DNA molecule.
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binding reactions that contain oligonucleotide probes with 0–
3 methylated CpGs. Based on the amounts of each protein
required to complex 50% of the probe, we calculated the
dissociation constants for 1xMBD and 4xMBD proteins
(Table 1). The results showed that 4xMBD has a 50–80-
fold higher affinity for substrates containing 1, 2 or 3 methy-
lated CpGs than does 1xMBD. The affinity of 4xMBD for
the probe with 3 methyl-CpG moieties was 20 nM. To
test whether the multimeric protein competes with a wild-
type methyl-CpG-binding protein for binding to methylated
DNA, increasing amounts of 4xMBD were added to band-
shift reactions that contained purified recombinant MeCP2.
As shown in Figure 2C, DNA–MeCP2 complexes were
competed away by the purified wild-type 4xMBD protein,
whereas the mutant R22A protein did not compete. A similar
result was obtained using nuclear extracts as a source of
MBPs (data not shown).
Detection of methylated DNA by NxMBD
proteins in vitro
We examined the sensitivity of methyl-CpG-binding in vitro
by incubating recombinant 1xMBD and 4xMBD plus
their mutant counterparts with nylon membranes carrying
either M.SssI-methylated or non-methylated bacteriophage
lambda DNA. The results showed that 4xMBD was able to
detect 0.1 ng of immobilized double-stranded DNA, whereas
1xMBD was more than 20-fold less sensitive in this assay
(Figure 3). Binding to methylated DNA was lost in the
R22A mutant proteins. No background staining of non-
methylated DNA (up to 250 ng) was detected with the poly-
MBD protein probes. For comparison, we probed equivalent
slot-blots with a commercially available anti-m5C antibody.
The antibody was 100-fold less sensitive than 4xMBD
when probed against native double-stranded methylated
DNA, but gave a comparable signal level when the immobi-
lized DNA was denatured. Denaturation abolished binding of
the MBD proteins to methylated DNA (data not shown).
We then asked whether the artificial MBD proteins were
able to access densely methylated heterochromatic foci in
fixed mouse fibroblasts. After incubation with NxMBD pro-
teins, bound proteins were immobilized by fixation to prevent
washout during the subsequent procedures. Incubation with
the wild-type protein resulted in characteristic staining of
DAPI-positive heterochromatin (Figure 4A and B). The incr-
eased affinity resulting from multimerization was apparent,
as 4 mg/ml of the tetrameric 4xMBD protein stained more
strongly than 50 mg/ml of monomeric 1xMBD (Figure 4A
and B). The 4xMBD protein also stained metaphase chromo-
somes at centromeric regions and along the chromosome
arms (Figure 4C). No signal on metaphase chromosomes
was detected using 1xMBD or the 1x or 4xMBD–R22A nega-
tive control proteins. Taken together with the slot-blot data
(Figure 3), these results indicate that 4xMBD is a sensitive
and specific reagent for the detection of CpG methylation
of double-stranded genomic DNA in the genome. Multi-
merization of the MBD does not compromise the specifi-
city of the MBD, as non-methylated DNA is not detectably
recognized.
In vivo binding of multimeric DNA to methyl-CpG sites
Following the in vitro studies described above, we analysed
the in vivo binding characteristics of NxMBD proteins. The
Table 1. Binding constants (mM) for 1xMBD and 4xMBD with probes that
have 1, 2 or 3 methyl-CpG moieties (1ME, 2ME and 3ME)
Protein 1ME 2ME 3ME
4xMBD 0.5 mMa 0.05 mMa 0.02 mMa
1xMBD 30 mMa 3 mMa 2 mMa
4x/1x ratio 55 59 81
aBinding constants were deduced from bandshift data shown in Figure 2 in
which probe (25 fmol) was incubated in 100 mM salt with 3–300 nmol
1xMBD or 1–100 nmol 3xMBD (see Materials and Methods).
Figure 2. Multimerization of the MBD increases the affinity for methylated
DNA. Increasing amounts (2.5, 5, 10, 15, 25, 50, 75, 100 ng) of wild-type
1xMBD (A) or 4xMBD protein (B) were incubated with duplex oligonucleo-
tide probes containing either 0, 1, 2 or 3 methyl-CpGs (0ME, 1ME, 2ME and
3ME, respectively). The complexes were resolved on 6% polyacrylamide
gels. (C) Multimeric MBD protein can displace the methyl-CpG-binding
protein MeCP2 from methylated DNA in vitro. Increasing amounts of wild-
type 4xMBD (2.5, 10, 25, 100, 250 ng) or control 4xMBD–R22A (2.5, 10, 25,
100, 250 ng) tetrameric protein were added to reactions containing 150 ng
recombinant GST–MeCP2 fusion protein (rMeCP2) and incubated with the
2ME oligonucleotide probe (see above). Both MBD proteins and MeCP2
were present in the reactions before the addition of the labelled probe. The
absence of multiple bands as seen with the CG11 probe (Figure 1) may be
explained by the small number of CpGs in 2ME and 3ME probes (2 or 3
compared to 27 in CG11) and the use of polyacrylamide rather than agarose
gel for fractionation of complexes.
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proteins were expressed in mouse fibroblasts and detected
using an anti-HA antibody. As expected, the wild-type pro-
teins co-localized with methyl-CpG-dense heterochromatic
foci (Figure 5A). 4xMBD showed significantly more intense
staining than 1xMBD, in agreement with the in vitro analysis.
The negative control proteins (R22A) did not co-localize
with the heterochomatic foci (data not shown). As a further
control for the specificity of in vivo binding, we found that
Figure 3. Recombinant 4xMBD proteins is a sensitive detection reagent for methylated CpG in immobilized DNA. CpG methylated (M) or unmethylated (U)
lambda phage DNA was immobilized on membranes and detected using the indicated NxMBD proteins (10 mg/ml) followed by anti-HA and HRP-anti-mouse
antibody, or with anti-m5C antibody (1:500) followed by HRP-anti-mouse antibody. The amount of DNA in each slot is indicated at the left. Native DNA (native)
was blotted on to nitrocellulose membrane and denatured (denat) DNA was blotted on to nylon membranes. The bottom right slot on each filter contained 50 ng
of HA-tagged 1xMBD as a positive control.
Figure 4. The 4xMBD protein is a sensitive stain for methyl-CpG-rich regions in fixed cells. Permeabilized and fixed mouse fibroblasts were incubated with
50 mg/ml 1xMBD (A) or 4 mg/ml 4xMBD (B), or their R22A mutant forms, and visualized with anti-HA plus Alexa-594-conjugated anti-mouse antibodies.
Specific staining is seen at heterochromatic DAPI bright spots with the wild-type probe but not with their mutant counterparts. Weak staining by the 4xMBD–
R22A mutant protein is sometimes detected, but does not co-localize with DAPI bright spots. Staining shows improved resolution with 4xMBD compared to
1xMBD and requires >10-fold less protein. (C) Metaphase spreads from mouse fibroblasts were incubated with 4 mg/ml 4xMBD and visualized with anti-HA
plus Alexa-594-conjugated anti-mouse antibodies. DNA is counterstained with DAPI. Intense staining of pericentromeric satellite DNA is apparent plus weaker
staining of the chromosome arms.
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heterochromatic localization of wild-type 4xMBD proteins
was lost in cells that lack Dnmt1 (17) and, hence, have
greatly reduced levels of CpG methylation (Figure 5B).
To determine whether 4xMBD could recruit a functional
domain to non-heterochromatic methylated sites in vivo, the
4xMBD protein was fused to the VP16-activation domain
and expressed in cells that also received reporter constructs.
As shown in Figure 5C, the 4xMBD–VP16 fusion caused
a 100-fold increase in expression from a methylated
reporter, whereas unfused 4xMBD protein had no effect.
A slight induction (2-fold) of the non-methylated cons-
truct by 4xMBD–VP16 was observed, which may be due to
non-specific effects of its strong activation domain. Staining
of cells transfected with the 4xMBD–VP16 construct demon-
strated that the overall localization of the fusion protein
is indistinguishable from that of non-fusion 4xMBD
(Figure 5A). We conclude that MBD is available to interact
with euchromatic methylated sites and can recruit a
functional domain to these sites in vivo.
CONCLUSIONS
We demonstrate here that the 4xMBD polypeptide has a high
affinity for methyl-CpG sites in vitro and in vivo. Multimer-
ization significantly amplifies the affinity without loss of
specificity as measured by interaction with (i) methylated
DNA in solution, (ii) DNA immobilized on membranes
and (iii) chromosomal DNA in cytological preparations.
These methods consistently suggest a 100-fold enhance-
ment of binding due to tetramerization compared with the
monomeric MBD. In spite of this improved binding, we
saw little evidence for loss of specificity, as non-methylated
DNA was negative for interaction with the 4xMBD poly-
peptide by all assays. Available antibodies raised against
the m5C base require DNA to be denatured by heat or alkali
in order to fully expose the epitope. An advantage of the
poly-MBD proteins is that they recognize methyl-CpG in
duplex DNA and therefore do not require cytological prepa-
rations to be subjected to harsh denaturing conditions that
may compromise specimen integrity. Also, 4xMBD can be
produced in the laboratory simply and relatively cheaply by
expression in bacteria. Poly-MBD proteins can therefore be
considered as an alternative to anti-m5C antibodies as sensi-
tive and specific reagents for the detection of methyl-CpG
sites in genomic DNA.
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